 FOSTER CITY, Calif., April 04, 2022 GLOBE NEWSWIRE -- Terns Pharmaceuticals, Inc. Terns or the Company Nasdaq: TERN, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis NASH and obesity, today announced that management will be presenting at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11 at 2:15 p.m. ET. 